IL23R and inflammatory bowel disease: In the context of IBD, intestinal antigens—including those derived from the microbiota (e.g., flagellins) and inflammation-related molecules (e.g., IL-23R)—are increasingly recognized as relevant targets for Treg-based interventions [30, 31].